Nasdaq

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm The FDA-approved strength for both COPD and asthma is fluticasone furoate / ...
Yahoo

GSK's three-drug inhaler wins U.S. nod for use in asthma patients

(Reuters) - GlaxoSmithKline Plc said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler delivering three drugs at once ...
AOL

What Does a Trelegy Inhaler Cost with Medicare?

Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...
Becker's Hospital Review

FDA approves Glaxo’s triple therapy inhaler for COPD

The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with the ...
FiercePharma

GlaxoSmithKline eyes novel death-risk reduction update to Trelegy's label, but analysts say the FDA may not be impressed

GlaxoSmithKline has seized the initiative with its three-drug COPD inhaler Trelegy Ellipta despite some new competition from AstraZeneca. To cement its lead, GSK is looking for a first-of-its-kind ...
FiercePharma

GlaxoSmithKline earns FDA nod for triple-drug combo Trelegy in sought-after asthma patients

With a handy lead in COPD, GlaxoSmithKline's Trelegy Ellipta has been positioned well as the leading triple-drug inhaler on the market. But with a major competitor gaining speed, GSK is looking to pad ...
Healio

FDA approves Trelegy Ellipta for new asthma indication

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Trelegy Ellipta, once-daily, single-inhaler triple therapy, for the new indication of ...
Business Wire

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

LONDON & BURLINGAME, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication ...
Metro US

GSK’s three-drug inhaler wins U.S. nod for use in asthma patients

(Reuters) – GlaxoSmithKline Plc said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler delivering three drugs at once ...
Nasdaq

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm The FDA-approved strength for both COPD and asthma is fluticasone furoate / ...
Business Wire

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US | Business Wire

Pavel Raifeld, Chief Executive Officer of Innoviva, said: “ In 2017, Trelegy Ellipta was approved in the US as the first once-daily single inhaler triple therapy for the treatment of COPD, and it ...